Superworth

Cue Biopharma EPS CUE

Diluted earnings per share by quarter and over the last twelve months, from 2017.

Last 12 months, to Jun 30, 2026
−$27.02
Latest quarter, Q2 FY26
−$24.14
Fiscal year 2025
−$9.42

Cue Biopharma's earnings per share was −$27.02 over the twelve months to Jun 30, 2026.

In its latest quarter, Q2 FY26, it was −$24.14.

Earnings per share over time

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearEPSChange
FY2025−$9.42n/a
FY2024−$22.50n/a
FY2023−$33.00n/a
FY2022−$44.70n/a
FY2021−$42.30n/a
FY2020−$47.10n/a
FY2019−$50.40n/a
FY2018−$57.90n/a
FY2017−$64.20n/a

Each fiscal year is the twelve months to its fourth quarter.

Quarter by quarter

QuarterEndedEPSOn a year earlierLast 12 months
Q2 FY26−$24.14n/a−$27.02
Q1 FY26−$1.08n/a−$5.55
Q4 FY25$0.30n/a−$9.42
Q3 FY25−$2.10n/a−$13.62
Q2 FY25−$2.67n/a−$16.62
Q1 FY25−$4.95n/a−$19.95
Q4 FY24−$3.90n/a−$22.50
Q3 FY24−$5.10n/a−$27.00
Q2 FY24−$6.00n/a−$29.10
Q1 FY24−$7.50n/a−$31.80
Q4 FY23−$8.40n/a−$33.00
Q3 FY23−$7.20n/a−$35.70

Against its peers

Companies in Drug Manufacturers - General nearest Cue Biopharma's size, closest first, today.

CompanyEPS, 12 monthsGrowth
CUECue Biopharma−$27.02
NATRNatures Sunshine Products$1.01+36% a year
LFVNLifevantage$0.40−46% a year
SPROSpero Therapeutics$0.11
ATNMActinium Pharmaceuticals$0.36
ARVNArvinas$0.16
PBYIPuma Biotechnology$0.52−47% a year
IRWDIronwood Pharmaceuticals$0.77
ZVRAZevra Therapeutics$0.93
CRMDCorMedix$2.13+184% a year
COLLCollegium Pharmaceutical$1.24+19% a year
Peer median$0.65

What the EPS figure tells you

Net income divided by diluted shares. The denominator of PE.

One-off charges and gains swing it. The TTM view smooths a single odd quarter.

More on Cue Biopharma

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.